Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials.
Three new medications show varying effectiveness against fatty liver disease, giving doctors better evidence to choose treatments tailored to individual patients.
This meta-analysis compared tirzepatide, lanifibranor, and resmetirom for metabolic dysfunction-associated steatotic liver disease using only high-quality RCT data. The results inform comparative effectiveness in a disease with growing pharmacotherapy options.
What the study was
- Study design
- Meta-analysis of RCTs
- Population
- MASLD patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Internal and Emergency Medicine
Why it surfaced
Comparative meta-analysis of 3 novel MASLD drugs (tirzepatide included). Relevant to cardiometabolic watchlist. RCT-grade evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.